Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Solid Biosciences Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 56 | 80 | +24 |
| Shares | 35.0M | 37.6M | +2.61M (+7.4%) |
| Value | $465.9M | $213.2M | −$252.7M (−54.2%) |
New holders (30)
Institutions that held Solid Biosciences Inc. at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (6)
Institutions that held Solid Biosciences Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Man Group plc | 48,922 | $651.6K |
| Marathon Trading Investment Management LLC | 37,300 | $496.8K |
| Balyasny Asset Management LLC | 23,525 | $313.4K |
| Raymond James Financial Services Advisors, Inc. | 13,259 | $176.6K |
| First Manhattan Co | 133 | $1.77K |
| Macquarie Group Ltd | 1,267 | $17 |